Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Expert Opinion on Biological Therapy
Sofia GentaGiorgio Valabrega

Abstract

Epithelial ovarian cancer (EOC) is the most common cause of death among gynecological malignancies. Despite surgical and pharmacological efforts to improve patients' outcome, persistent and recurrent EOC remains an un-eradicable disease. Chimeric associated antigens (CAR) T cells are T lymphocytes expressing an engineered T cell receptor that activate the immune response after an MHC unrestricted recognition of specific antigens, including tumor associated antigens (TAAs). CART cells have been shown to be effective in the treatment of hematologic tumors even if frequently associated with potentially severe toxicity and high production costs. In this review, we will focus on preclinical and clinical studies evaluating CART activity in EOC in order to identify possible difficulties and advantages of their use in this particular setting. The pattern of diffusion within the peritoneal cavity, the tumor microenvironment and the high rate of TAAs make EOC a particularly interesting model for CART cells use. Data from preclinical studies indicate a potential activity of CARTs in EOC, but robust clinical data are still awaited. Further studies are needed to determine the best methods of administration and the most effective CAR type to...Continue Reading

References

Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K Chang, I Pastan
Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael H KershawPatrick Hwu
Nov 21, 2007·Nature·Catherine M KoebelRobert D Schreiber
Mar 24, 2009·Current Opinion in Immunology·Steven A Rosenberg, Mark E Dudley
Dec 17, 2009·The Journal of Experimental Medicine·Loise M FranciscoArlene H Sharpe
Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard A MorganSteven A Rosenberg
Apr 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Renier BrentjensMichel Sadelain
Apr 14, 2010·Proceedings of the National Academy of Sciences of the United States of America·Junko MatsuzakiKunle Odunsi
Jul 16, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alena A ChekmasovaRenier J Brentjens
Jan 29, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Philipp HarterAndreas du Bois
May 18, 2011·Cancer Treatment Reviews·Carlo PatriarcaHakan Mellstedt
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Nov 4, 2011·The New England Journal of Medicine·Antonio Di StasiMalcolm K Brenner
Jan 28, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jessica N McAlpineC Blake Gilks
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Nov 26, 2013·Frontiers in Immunology·Markus ChmielewskiHinrich Abken
Dec 18, 2013·Immunological Reviews·Gianpietro DottiMalcolm K Brenner
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Devansu TewariJohn K Chan
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nabil AhmedStephen Gottschalk
Apr 9, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven C KatzRichard P Junghans
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 20, 2015·Expert Opinion on Biological Therapy·Markus Chmielewski, Hinrich Abken
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Dec 26, 2015·Trends in Pharmacological Sciences·Daniel T Harris, David M Kranz

❮ Previous
Next ❯

Citations

Aug 8, 2019·Journal of Cachexia, Sarcopenia and Muscle·Jorne UbachsToon Van Gorp
Jul 28, 2018·Cancers·Curtis W McCloskeyBarbara C Vanderhyden
Aug 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liang WangManhua Cui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

© 2022 Meta ULC. All rights reserved